{
  "canine-atopic-dermatitis": {
    "zh": "犬異位性皮膚炎",
    "en": "Canine Atopic Dermatitis",
    "definition": "犬隻因遺傳易感性對環境過敏原（如塵蟎、花粉、黴菌）產生IgE介導的過敏反應，導致慢性復發性搔癢性皮膚病。",
    "synonyms": ["犬異位症", "Canine Atopy", "CAD"],
    "epidemiology": {
      "species": "犬，貓極少使用此診斷",
      "age": "通常1-3歲首次發病",
      "sex": "無明顯性別傾向",
      "riskFactors": ["品種遺傳（西高地白梗、拉布拉多、法鬥、金毛）", "都市環境", "家族過敏史"]
    },
    "clinicalPresentation": {
      "history": ["季節性或全年性搔癢", "反覆耳道感染", "搔癢先於皮膚病變出現", "症狀逐年惡化", "對類固醇治療反應良好"],
      "physicalExam": ["面部搔癢（眼周、口周）", "趾間紅腫及舔舐", "腋下及腹股溝紅斑", "耳廓內側紅腫", "慢性皮膚苔蘚化及色素沉著", "繼發性細菌或酵母菌感染"]
    },
    "pathophysiology": "皮膚屏障功能缺陷（如filaggrin基因異常）導致環境過敏原穿透皮膚，樹突細胞捕獲過敏原後呈現給Th2淋巴細胞，促使B細胞產生過敏原特異性IgE。IgE結合肥大細胞表面受體，再次接觸過敏原時引發脫顆粒反應，釋放組織胺和發炎介質，導致搔癢和發炎。",
    "diagnosis": {
      "overview": "臨床診斷為主，需排除其他搔癢性疾病。Favrot標準可輔助臨床診斷。",
      "differentials": ["跳蚤過敏性皮膚炎", "食物過敏", "疥癬", "毛囊蟲症", "接觸性皮膚炎", "細菌性膿皮症"],
      "initialDB": ["皮膚刮片排除外寄生蟲", "皮膚細胞學（排除感染）", "嚴格跳蚤防治試驗", "食物排除試驗（8-12週）"],
      "advanced": ["皮內過敏原測試（IDAT）", "血清過敏原特異性IgE檢測", "皮膚切片（非特異性但可排除其他疾病）"]
    },
    "treatment": {
      "overview": "多模式治療：避免過敏原、修復皮膚屏障、控制發炎和搔癢、管理繼發感染。",
      "acute": ["Oclacitinib（Apoquel）快速止癢", "短期類固醇（潑尼松龍0.5-1mg/kg）", "治療繼發性細菌或酵母菌感染", "外用類固醇噴劑"],
      "chronic": ["過敏原特異性免疫治療（ASIT/減敏療法）", "Lokivetmab（Cytopoint）每4-8週注射", "Oclacitinib長期口服", "環孢素（Atopica）", "必需脂肪酸補充", "定期藥浴和皮膚保濕"]
    },
    "prognosis": "無法治癒但可良好控制。多數病例需終身管理。過敏原特異性免疫治療約60-70%病例有效改善。早期診斷和多模式治療可顯著提升生活品質。",
    "pearls": ["Favrot標準：符合5/8項則敏感性85%、特異性79%", "搔癢出現在皮膚病變之前是異位性皮膚炎的特徵", "必須排除跳蚤過敏和食物過敏後才能確診", "繼發性感染是急性發作的常見原因"],
    "monitoring": ["搔癢評分（PVAS）", "皮膚感染復發頻率", "藥物副作用（肝腎功能）", "免疫治療反應評估"],
    "reference": "Hensel P et al. BMC Vet Res 2015; Olivry T et al. ICADA guidelines. Vet Dermatol 2015"
  },
  "flea-allergy-dermatitis": {
    "zh": "跳蚤過敏性皮膚炎",
    "en": "Flea Allergy Dermatitis",
    "definition": "對跳蚤唾液中的過敏原產生過敏反應，導致嚴重搔癢性皮膚炎。是犬貓最常見的過敏性皮膚病。",
    "synonyms": ["FAD", "跳蚤咬傷過敏", "Flea Bite Hypersensitivity"],
    "epidemiology": {
      "species": "犬貓皆常見",
      "age": "任何年齡，但通常1歲以上首次發病",
      "sex": "無性別傾向",
      "riskFactors": ["溫暖潮濕環境", "戶外活動", "跳蚤預防不足", "異位性體質"]
    },
    "clinicalPresentation": {
      "history": ["劇烈搔癢（尤其腰薦部）", "季節性或全年性（視氣候）", "跳蚤預防不規律", "同居動物可能無症狀"],
      "physicalExam": ["犬：腰薦部、尾根部、大腿內側丘疹性皮膚炎", "貓：粟粒性皮膚炎、嗜酸球性肉芽腫複合體", "脫毛（對稱性或局部）", "繼發性細菌感染", "跳蚤或跳蚤糞便可見（但敏感動物可能極少）"]
    },
    "pathophysiology": "跳蚤唾液含有多種半抗原和過敏原蛋白，可引發第I型（即發型）和第IV型（遲發型）過敏反應。敏感動物僅需少數跳蚤叮咬即可引發嚴重全身性搔癢。",
    "diagnosis": {
      "overview": "主要基於臨床表現、病變分布和對跳蚤控制的反應。",
      "differentials": ["異位性皮膚炎", "食物過敏", "疥癬", "皮膚真菌感染", "毛囊蟲症"],
      "initialDB": ["仔細梳毛尋找跳蚤或跳蚤糞便", "跳蚤糞便濕紙巾測試（紅棕色暈染）", "皮膚刮片排除其他寄生蟲"],
      "advanced": ["皮內過敏原測試（跳蚤抗原）", "嚴格跳蚤防治試驗（6-8週）作為診斷性治療", "皮膚切片（表淺血管周圍炎伴嗜酸球浸潤）"]
    },
    "treatment": {
      "overview": "核心為嚴格跳蚤預防和環境控制，輔以止癢和感染控制。",
      "acute": ["速效殺蚤劑（如Spinosad、Nitenpyram）", "短期類固醇止癢", "治療繼發性感染", "環境除蚤處理"],
      "chronic": ["全年持續性跳蚤預防（所有同居動物）", "Isoxazoline類藥物（如Fluralaner、Afoxolaner）", "環境控制（定期清洗寢具、吸塵）", "必需脂肪酸輔助"]
    },
    "prognosis": "嚴格跳蚤控制下預後極佳。關鍵在於所有同居動物都必須持續預防，且需配合環境除蚤。",
    "pearls": ["敏感動物上可能找不到跳蚤（因過度理毛移除）", "必須同時治療所有同居動物", "環境中95%的跳蚤族群是蟲卵和幼蟲", "貓的粟粒性皮膚炎是FAD的經典表現"],
    "monitoring": ["搔癢程度改善", "皮膚病變消退", "跳蚤預防依從性", "繼發感染控制"],
    "reference": "Dryden MW. Vet Dermatol 2009; Rust MK. Vet Dermatol 2005"
  },
  "cranial-cruciate-ligament-disease": {
    "zh": "前十字韌帶疾病",
    "en": "Cranial Cruciate Ligament Disease",
    "definition": "膝關節前十字韌帶（CCL）的退行性斷裂，導致關節不穩定、疼痛和進行性骨關節炎。是犬後肢跛行最常見的骨科原因。",
    "synonyms": ["前十字韌帶斷裂", "CCL斷裂", "ACL斷裂", "CCLD"],
    "epidemiology": {
      "species": "犬極常見，貓偶見",
      "age": "大型犬1-5歲，小型犬中老年",
      "sex": "絕育犬風險較高",
      "riskFactors": ["肥胖", "品種傾向（拉布拉多、羅威那、紐芬蘭）", "絕育", "脛骨平台角度過大", "對側CCL斷裂（40-60%在1-2年內）"]
    },
    "clinicalPresentation": {
      "history": ["急性後肢跛行（部分或完全斷裂）", "運動後跛行加重", "逐漸性後肢跛行", "坐下時患肢外伸", "雙側時起立困難"],
      "physicalExam": ["脛骨前推試驗陽性", "脛骨壓迫試驗陽性", "膝關節積液", "內側支持帶增厚（medial buttress）", "肌肉萎縮", "半月板彈響（meniscal click）"]
    },
    "pathophysiology": "犬CCL疾病主要為退行性過程而非急性創傷。韌帶隨時間退化、纖維斷裂逐漸增加，最終完全斷裂。關節不穩定導致半月板損傷和進行性骨關節炎。",
    "diagnosis": {
      "overview": "基於臨床檢查（脛骨前推和壓迫試驗）和影像學。",
      "differentials": ["髕骨脫位", "半月板損傷", "膝關節骨關節炎", "膝關節感染", "腫瘤"],
      "initialDB": ["骨科檢查（可能需鎮靜）", "膝關節X光（積液、骨贅）", "觸診脛骨前推/壓迫試驗"],
      "advanced": ["關節鏡檢查", "CT/MRI（評估半月板）", "關節液分析"]
    },
    "treatment": {
      "overview": "大型犬強烈建議手術穩定。小型犬可嘗試保守治療。",
      "acute": ["止痛（NSAIDs）", "限制活動", "冷敷消腫"],
      "chronic": ["手術治療（TPLO為首選）", "TTA（脛骨粗隆前移術）", "側向縫線穩定術（小型犬）", "術後復健（8-12週）", "體重管理", "關節保健品（葡萄糖胺、軟骨素）"]
    },
    "prognosis": "TPLO手術成功率約90-95%，大多數犬可恢復良好功能。未手術大型犬預後較差，進行性骨關節炎不可避免。小型犬保守治療約可接受但功能恢復較慢。",
    "pearls": ["40-60%的犬會在對側膝蓋發生CCL斷裂", "半月板損傷的彈響聲是手術探查的重要指標", "肥胖是最重要的可控風險因素", "急性非負重性跛行常伴隨半月板損傷"],
    "monitoring": ["術後X光追蹤", "對側膝關節評估", "體重管理", "骨關節炎進展", "活動功能評估"],
    "reference": "Kowaleski MP et al. Vet Surg 2012; Bergh MS et al. JAVMA 2014"
  },
  "hip-dysplasia": {
    "zh": "髖關節發育不良",
    "en": "Hip Dysplasia",
    "definition": "髖關節先天性發育異常，髖臼與股骨頭不匹配導致關節鬆弛、半脫位和進行性退行性關節病變。",
    "synonyms": ["CHD", "Canine Hip Dysplasia", "髖關節形成不良"],
    "epidemiology": {
      "species": "犬較常見，貓偶見",
      "age": "幼犬5-12月齡出現症狀，或中老年因骨關節炎就診",
      "sex": "無明顯性別差異",
      "riskFactors": ["品種遺傳（德國牧羊犬、拉布拉多、黃金獵犬、聖伯納）", "快速生長", "過度營養", "過早激烈運動"]
    },
    "clinicalPresentation": {
      "history": ["後肢跛行或僵硬", "起立困難", "運動不耐", "上下樓梯困難", "兔跳步態", "幼犬或老年犬兩個發病高峰期"],
      "physicalExam": ["Ortolani試驗陽性（幼犬）", "後肢肌肉萎縮", "髖關節伸展疼痛", "活動範圍減少", "骨關節炎的捻髮音"]
    },
    "pathophysiology": "遺傳性多基因疾病，髖關節在發育過程中韌帶鬆弛導致關節不穩定，股骨頭與髖臼間的異常磨損引發軟骨退化和骨關節炎。環境因素（過度生長、肥胖）加速病程。",
    "diagnosis": {
      "overview": "結合臨床檢查和影像學確診。",
      "differentials": ["腰薦椎疾病", "前十字韌帶疾病", "多發性關節炎", "股骨頭無菌性壞死（Legg-Perthes病）"],
      "initialDB": ["骨科理學檢查", "Ortolani試驗（鎮靜下）", "骨盆腔X光（標準伸展位）"],
      "advanced": ["PennHIP壓力X光", "CT掃描", "關節液分析"]
    },
    "treatment": {
      "overview": "依年齡和嚴重程度選擇保守或手術治療。",
      "acute": ["止痛（NSAIDs）", "限制活動", "體重管理"],
      "chronic": ["保守治療（體重控制、適度運動、NSAIDs、關節保健品）", "幼犬預防性手術（JPS恥骨聯合固定術<16週）", "DPO/TPO（三聯骨盆截骨術）", "全髖關節置換術（THR）", "股骨頭頸切除術（FHNE，小型犬）", "物理治療和水療"]
    },
    "prognosis": "輕度發育不良經保守治療可維持良好生活品質。嚴重病例全髖關節置換術後95%以上可恢復正常功能。FHNE在小型犬效果良好。",
    "pearls": ["PennHIP是評估髖關節鬆弛度最客觀的方法", "過度補鈣反而加重發育不良", "控制幼犬生長速度比限制運動更重要", "雙側X光常見不對稱表現"],
    "monitoring": ["體重控制", "活動功能評估", "X光追蹤骨關節炎進展", "疼痛評估"],
    "reference": "Smith GK et al. JAVMA 2001; Vezzoni A et al. Vet Comp Orthop Traumatol 2008"
  },
  "patellar-luxation": {
    "zh": "髕骨脫位",
    "en": "Patellar Luxation",
    "definition": "髕骨從股骨滑車溝中移位，可為內側或外側脫位，導致間歇性或持續性後肢跛行。",
    "synonyms": ["膝蓋骨脫位", "髕骨脫臼", "Trick Knee"],
    "epidemiology": {
      "species": "犬較常見（小型犬內側脫位），貓偶見",
      "age": "先天性可早期發現，臨床症狀常在成年後出現",
      "sex": "母犬略多（1.5:1）",
      "riskFactors": ["小型犬種（貴賓、吉娃娃、約克夏、博美）", "大型犬外側脫位", "先天性骨骼畸形"]
    },
    "clinicalPresentation": {
      "history": ["間歇性跳躍式跛行（skipping gait）", "突然抬腿數步後恢復正常", "運動後僵硬", "嚴重者持續跛行"],
      "physicalExam": ["髕骨可手動推移（分級I-IV）", "Grade I：可推出但自行復位", "Grade II：可推出或自行脫位，可手動復位", "Grade III：持續脫位，可手動復位但立即脫出", "Grade IV：持續脫位，無法手動復位", "股骨內旋（內側脫位）"]
    },
    "pathophysiology": "先天性股骨滑車溝淺化、脛骨粗隆內側（或外側）偏移、股四頭肌力線偏移等骨骼排列異常，導致髕骨無法穩定在滑車溝中。長期脫位可導致軟骨磨損和前十字韌帶損傷。",
    "diagnosis": {
      "overview": "理學檢查即可診斷和分級。影像學評估骨骼畸形程度。",
      "differentials": ["前十字韌帶疾病", "髖關節疾病", "股骨頭壞死（Legg-Perthes）", "骨折"],
      "initialDB": ["觸診分級", "步態分析", "膝關節X光"],
      "advanced": ["CT評估骨骼畸形", "同時評估前十字韌帶完整性"]
    },
    "treatment": {
      "overview": "Grade I通常不需手術。Grade II以上或有臨床症狀建議手術矯正。",
      "acute": ["止痛（NSAIDs）", "限制活動"],
      "chronic": ["手術矯正（滑車溝加深術）", "脛骨粗隆轉位術", "外側關節囊縮縫術", "嚴重畸形需矯正截骨術", "術後限制活動6-8週", "體重管理"]
    },
    "prognosis": "Grade I-II手術矯正成功率高（>90%）。Grade III-IV預後較謹慎，可能需更複雜的矯正手術。術後10-15%復發率。早期手術可預防骨關節炎和CCL損傷。",
    "pearls": ["15-20%的髕骨脫位犬會合併CCL斷裂", "內側脫位佔小型犬的90%以上", "Grade II以上建議預防性手術以避免關節退化", "雙側脫位佔50%病例"],
    "monitoring": ["術後X光", "跛行程度", "對側膝關節", "骨關節炎發展"],
    "reference": "Roush JK. Vet Clin North Am Small Anim Pract 2005; Arthurs GI et al. Vet Comp Orthop Traumatol 2006"
  },
  "osteoarthritis": {
    "zh": "骨關節炎",
    "en": "Osteoarthritis",
    "definition": "關節軟骨進行性退化伴隨滑膜發炎和骨贅增生的慢性退行性關節疾病，導致疼痛和功能障礙。",
    "synonyms": ["退行性關節病", "DJD", "Degenerative Joint Disease"],
    "epidemiology": {
      "species": "犬貓皆常見（貓常被低估）",
      "age": "中老年多見，但可繼發於幼年關節疾病",
      "sex": "無明顯性別差異",
      "riskFactors": ["肥胖", "先前關節損傷或手術", "關節發育不良", "品種傾向", "高強度工作犬"]
    },
    "clinicalPresentation": {
      "history": ["漸進性僵硬和跛行", "晨起僵硬（暖身後改善）", "天冷時症狀加重", "活動量減少", "貓：跳躍減少、理毛減少、脾氣改變"],
      "physicalExam": ["關節腫脹", "活動範圍減少", "捻髮音", "關節周圍肌肉萎縮", "關節屈伸時疼痛", "貓：常缺乏明顯跛行但活動力下降"]
    },
    "pathophysiology": "關節軟骨因機械壓力和發炎介質損傷逐漸退化。軟骨細胞代償性增殖不足以修復損傷，軟骨下骨暴露，滑膜發炎釋放更多發炎介質（IL-1、TNF-α、PGE2），形成惡性循環。邊緣骨贅增生為代償性反應。",
    "diagnosis": {
      "overview": "結合臨床檢查和影像學。貓需仔細觀察行為變化。",
      "differentials": ["免疫媒介性關節炎", "感染性關節炎", "關節腫瘤", "韌帶損傷"],
      "initialDB": ["完整骨科檢查", "X光（骨贅、關節腔狹窄、軟骨下硬化）", "步態分析"],
      "advanced": ["關節液分析", "CT/MRI", "壓力板步態分析", "血液檢查排除全身性疾病"]
    },
    "treatment": {
      "overview": "多模式鎮痛、體重管理和維持關節功能為核心。無法治癒但可良好管理。",
      "acute": ["NSAIDs（Meloxicam、Carprofen）", "鴉片類止痛（嚴重疼痛）", "冷敷或熱敷", "限制活動"],
      "chronic": ["體重管理（最重要的單一措施）", "長期NSAIDs", "Librela（犬抗NGF單抗）/ Solensia（貓抗NGF單抗）", "關節保健品（葡萄糖胺、Omega-3脂肪酸）", "物理治療和水療", "環境改善（防滑墊、斜坡、矮食碗）", "適度規律運動"]
    },
    "prognosis": "進行性疾病，無法治癒但通過多模式管理可長期維持良好生活品質。早期介入效果較好。貓OA嚴重低診率，提高認知很重要。",
    "pearls": ["貓的OA發生率可能高達90%（>12歲），但極少表現典型跛行", "體重減輕6-8%即可顯著改善症狀", "抗NGF單抗（Librela/Solensia）是近年突破性治療", "X光嚴重程度與臨床症狀不一定相關"],
    "monitoring": ["疼痛評分（如CBPI犬簡短疼痛量表）", "活動功能", "體重", "NSAIDs長期使用的腎肝功能監測"],
    "reference": "Innes JF. Vet Surg 2022; Gruen ME et al. JAVMA 2022"
  },
  "mast-cell-tumor": {
    "zh": "肥大細胞瘤",
    "en": "Mast Cell Tumor",
    "definition": "起源於肥大細胞的腫瘤，是犬最常見的皮膚惡性腫瘤。生物學行為差異極大，從良性到高度惡性。",
    "synonyms": ["MCT", "肥大細胞肉瘤", "Mastocytoma"],
    "epidemiology": {
      "species": "犬最常見（佔皮膚腫瘤16-21%），貓皮膚型多為良性",
      "age": "中老年犬（平均8-9歲）",
      "sex": "無明顯性別傾向",
      "riskFactors": ["品種傾向（拳師犬、波士頓梗、拉布拉多、金毛、巴哥）", "短頭犬種", "先前MCT病史"]
    },
    "clinicalPresentation": {
      "history": ["皮膚或皮下腫塊", "腫塊大小可能波動（脫顆粒反應）", "反覆腫脹和消退", "病程數週至數月"],
      "physicalExam": ["皮膚腫塊外觀多變（偽裝大師）", "Darier徵象（觸摸後紅腫）", "局部紅腫水腫", "區域淋巴結腫大", "內臟型可見脾肝腫大"]
    },
    "pathophysiology": "肥大細胞惡性增生，含有大量組織胺、肝素和蛋白酶等生物活性物質的顆粒。脫顆粒可導致局部水腫、潰瘍、全身性組織胺釋放效應（胃潰瘍、低血壓、凝血障礙）。c-KIT基因突變在部分MCT中扮演重要角色。",
    "diagnosis": {
      "overview": "細針抽吸細胞學即可快速診斷。組織病理分級對預後至關重要。",
      "differentials": ["其他皮膚腫瘤（脂肪瘤、組織球瘤）", "蟲咬反應", "肉芽腫", "皮膚感染"],
      "initialDB": ["細針抽吸細胞學（特徵性紫色顆粒）", "區域淋巴結抽吸", "腹部超音波（肝脾）"],
      "advanced": ["切除組織病理分級（Patnaik或Kiupel系統）", "c-KIT突變分析", "Ki67增殖指數", "AgNOR", "胸部X光", "骨髓抽吸（高級別）"]
    },
    "treatment": {
      "overview": "手術切除是低-中級別MCT的首選治療。高級別需輔助化療或放療。",
      "acute": ["術前抗組織胺（H1和H2阻斷劑）", "胃黏膜保護劑", "廣泛手術切除（2-3cm邊界）"],
      "chronic": ["高級別：Vinblastine + Prednisolone化療", "c-KIT突變陽性：Toceranib（Palladia）或Masitinib（Masivet）", "放射治療（邊界不完整）", "低級別完整切除可能不需輔助治療"]
    },
    "prognosis": "低級別完整切除預後優良（中位存活>4年）。高級別中位存活約6個月。c-KIT突變陽性對酪氨酸激酶抑制劑反應良好。Kiupel二級分類系統（低/高）臨床使用較為簡便。",
    "pearls": ["MCT是犬腫瘤的偽裝大師，任何皮膚腫塊都應抽吸", "術前使用H1+H2抗組織胺可減少脫顆粒併發症", "不要擠壓MCT以避免大量脫顆粒", "拳師犬的MCT通常級別較低，預後較好"],
    "monitoring": ["切除部位復發", "區域淋巴結", "腹部超音波（肝脾）", "新發皮膚腫塊"],
    "reference": "London CA et al. Vet Clin North Am 2014; Kiupel M et al. Vet Pathol 2011"
  },
  "hemangiosarcoma": {
    "zh": "血管肉瘤",
    "en": "Hemangiosarcoma",
    "definition": "起源於血管內皮細胞的高度惡性腫瘤，最常見於脾臟，轉移率極高且預後差。",
    "synonyms": ["HSA", "血管內皮肉瘤", "Angiosarcoma"],
    "epidemiology": {
      "species": "犬較常見，貓罕見",
      "age": "中老年犬（8-13歲）",
      "sex": "公犬略多",
      "riskFactors": ["品種傾向（德國牧羊犬、黃金獵犬、拉布拉多）", "大型犬", "皮膚型與日曬暴露相關（毛髮稀疏犬）"]
    },
    "clinicalPresentation": {
      "history": ["急性虛脫或昏厥（脾臟腫瘤破裂出血）", "間歇性虛弱（反覆少量出血自行吸收）", "食慾下降", "腹部膨大", "運動不耐"],
      "physicalExam": ["黏膜蒼白", "心率加快", "腹部觸診可及腫塊", "腹腔積液（血腹）", "心包積液（心臟型）", "脾臟腫大", "皮膚型：暗紅色皮下腫塊"]
    },
    "pathophysiology": "血管內皮細胞惡性增生形成異常血管通道，腫瘤血管壁脆弱極易破裂。脾臟型最常見（約50%），其次為右心房、肝臟和皮下。血行轉移迅速，最常轉移至肝臟和肺臟。常合併DIC和微血管病性溶血性貧血。",
    "diagnosis": {
      "overview": "影像學發現脾臟腫塊為起點，但確診需組織病理。急診常因脾臟破裂出血而診斷。",
      "differentials": ["脾臟血腫", "其他脾臟腫瘤（淋巴瘤、結節性增生）", "心包積液其他原因", "腹腔內出血其他原因"],
      "initialDB": ["全血球計數（貧血、紅血球碎片）", "凝血功能（DIC篩查）", "腹部超音波", "胸部X光", "心臟超音波"],
      "advanced": ["腹腔穿刺液分析（PCV比對）", "脾臟切除後組織病理確診", "CT分期", "凝血功能全套"]
    },
    "treatment": {
      "overview": "脾臟切除是初始治療，但單獨手術預後很差，需輔助化療。",
      "acute": ["急診穩定（靜脈輸液、輸血）", "緊急脾臟切除止血", "心包穿刺引流（心包積液型）"],
      "chronic": ["Doxorubicin為基礎的化療方案", "Doxorubicin + Cyclophosphamide", "Metronomic化療", "皮膚型：廣泛切除可能治癒", "I'm-Yunity（雲芝多醣體）輔助"]
    },
    "prognosis": "內臟型預後極差。單獨脾臟切除中位存活1-3個月。脾切除加化療中位存活4-6個月。皮膚真皮型預後最好。心臟型預後最差。約2/3的脾臟腫塊在犬為惡性。",
    "pearls": ["德國牧羊犬和黃金獵犬的脾臟腫塊應高度懷疑HSA", "急性腹腔內出血的老年大型犬首先考慮脾臟HSA破裂", "血液抹片上的紅血球碎片（裂紅血球）是重要線索", "心包積液鑑別最常見的兩個原因是HSA和心基部腫瘤"],
    "monitoring": ["腹部超音波追蹤", "胸部X光", "全血球計數", "凝血功能", "心臟超音波（心臟型）"],
    "reference": "Clifford CA et al. JAVMA 2000; Thamm DH. Withrow & MacEwen's Small Animal Clinical Oncology, 6th Ed. 2020"
  },
  "mammary-tumor": {
    "zh": "乳腺腫瘤",
    "en": "Mammary Tumor",
    "definition": "起源於乳腺組織的腫瘤，犬約50%為惡性，貓約85-90%為惡性。是未絕育母犬最常見的腫瘤。",
    "synonyms": ["乳腺癌", "乳房腫瘤", "Mammary Gland Tumor"],
    "epidemiology": {
      "species": "犬貓皆常見（未絕育母犬/貓）",
      "age": "中老年（犬平均10-11歲，貓平均10-12歲）",
      "sex": "母犬/貓為主，公犬/貓極少且多為惡性",
      "riskFactors": ["未絕育或晚期絕育", "外源性黃體素使用", "肥胖（幼年期）", "犬：初情前絕育風險<0.5%，第一次發情後絕育8%，第二次後26%"]
    },
    "clinicalPresentation": {
      "history": ["乳腺區域腫塊", "逐漸增大", "可能有乳頭分泌物", "炎性乳腺癌：急性紅腫疼痛"],
      "physicalExam": ["乳腺鏈上單發或多發腫塊", "犬後兩對乳腺最常見", "腫塊固著於皮膚或深層", "區域淋巴結腫大", "炎性乳腺癌：瀰漫性紅腫水腫"]
    },
    "pathophysiology": "荷爾蒙（雌激素和黃體素）刺激乳腺上皮細胞增生，長期刺激增加突變累積和惡性轉化風險。惡性腫瘤可局部侵犯和經淋巴及血行轉移至肺、肝、骨和腦。貓乳腺腫瘤大多為侵襲性腺癌。",
    "diagnosis": {
      "overview": "組織病理學是確診和分類的金標準。術前分期很重要。",
      "differentials": ["乳腺增生", "乳腺炎", "脂肪瘤", "其他皮膚腫瘤"],
      "initialDB": ["完整乳腺鏈觸診", "胸部X光（三視圖肺轉移篩查）", "腹部超音波", "區域淋巴結抽吸"],
      "advanced": ["切除組織病理分類和分級", "免疫組織化學（ER/PR）", "CT分期", "荷爾蒙受體分析"]
    },
    "treatment": {
      "overview": "手術切除為主要治療，貓建議積極手術。同時絕育可能降低復發風險。",
      "acute": ["手術切除", "犬：腫塊切除至單側乳腺鏈切除", "貓：建議雙側乳腺鏈切除", "同時施行卵巢子宮切除術"],
      "chronic": ["惡性高級別：Doxorubicin或Carboplatin化療", "Carboplatin對犬乳腺癌效果", "抗荷爾蒙治療研究中", "炎性乳腺癌：NSAIDs輔助"]
    },
    "prognosis": "犬良性腫瘤手術治癒。犬惡性腫瘤<3cm且未轉移預後良好。貓乳腺腫瘤預後較差，<2cm中位存活>3年，>3cm中位存活約4-12個月。炎性乳腺癌預後極差。腫瘤大小是最重要的預後因素。",
    "pearls": ["早期絕育是最有效的預防措施", "貓乳腺腫瘤應視為惡性直到證明為良性", "腫瘤大小是犬貓最重要的預後因素", "炎性乳腺癌常被誤診為乳腺炎"],
    "monitoring": ["術後胸部X光（每3個月，持續2年）", "手術部位觸診", "對側乳腺鏈", "區域淋巴結"],
    "reference": "Sorenmo KU et al. Vet Pathol 2011; Zappulli V et al. Vet Pathol 2015"
  },
  "feline-infectious-peritonitis": {
    "zh": "貓傳染性腹膜炎",
    "en": "Feline Infectious Peritonitis",
    "definition": "由貓冠狀病毒突變株引起的致死性免疫介導性全身性疾病，分為滲出型（濕型）和非滲出型（乾型）。",
    "synonyms": ["FIP", "貓傳腹"],
    "epidemiology": {
      "species": "貓",
      "age": "幼貓（3月-2歲）和老年貓（>10歲）風險最高",
      "sex": "公貓略多",
      "riskFactors": ["多貓環境（收容所、繁殖場）", "幼貓", "純種貓", "免疫抑制", "應激"]
    },
    "clinicalPresentation": {
      "history": ["漸進性食慾下降和消瘦", "反覆發燒（對抗生素無反應）", "腹部膨大（濕型）", "慢性病程", "可能有上呼吸道感染史"],
      "physicalExam": ["濕型：腹水和/或胸水、黃疸", "乾型：肉芽腫性器官病變、葡萄膜炎、神經症狀", "發燒", "黃疸", "腎臟不規則增大", "腸系膜淋巴結腫大"]
    },
    "pathophysiology": "腸道貓冠狀病毒（FECV）在個體內突變為能在巨噬細胞內複製的FIPV。感染的巨噬細胞引發免疫介導性血管炎和肉芽腫。Th1反應佔優勢→乾型；抗體介導反應→免疫複合物沉積→血管炎→滲出型。",
    "diagnosis": {
      "overview": "確診困難，需綜合臨床、實驗室和病理學證據。近年GS-441524治療的出現使早期診斷更加重要。",
      "differentials": ["淋巴瘤", "細菌性腹膜炎", "心臟病（胸水）", "肝病（腹水）", "弓蟲症"],
      "initialDB": ["腹水/胸水分析（蛋白質>35g/L、Rivalta試驗陽性）", "全血球計數（淋巴球減少）", "生化（高球蛋白血症、A/G比<0.4）", "冠狀病毒抗體力價"],
      "advanced": ["積液RT-PCR", "積液免疫細胞化學", "組織切片免疫組織化學（確診）", "AGP（α1酸性糖蛋白升高）"]
    },
    "treatment": {
      "overview": "GS-441524和Molnupiravir等抗病毒藥物已革命性地改變FIP治療。過去被認為幾乎100%致命的疾病現在有高治癒率。",
      "acute": ["GS-441524注射（初期）", "支持療法（輸液、營養支持）", "腹水/胸水引流（呼吸窘迫時）", "發燒和疼痛管理"],
      "chronic": ["GS-441524口服或注射（84天療程）", "Molnupiravir（替代選擇）", "神經型和眼型可能需更高劑量和更長療程", "營養支持和症狀管理", "定期監測確認治癒"]
    },
    "prognosis": "使用GS-441524治療，濕型治癒率約80-90%，乾型約70-80%，神經型約60-70%。未治療幾乎100%致命。復發率約10-15%，多在停藥後3個月內。",
    "pearls": ["冠狀病毒抗體力價高不等於FIP，大多數陽性貓不會發病", "Rivalta試驗是簡便有效的積液初步篩查", "A/G比<0.4高度提示FIP", "GS-441524的出現徹底改變了FIP的預後"],
    "monitoring": ["治療期間：臨床症狀、體重、血液檢查（球蛋白、A/G比、AGP）", "停藥後3個月密切追蹤", "復發監測"],
    "reference": "Pedersen NC et al. J Feline Med Surg 2019; Tasker S. J Feline Med Surg 2023"
  },
  "feline-leukemia-virus": {
    "zh": "貓白血病病毒感染",
    "en": "Feline Leukemia Virus Infection",
    "definition": "貓白血病病毒（FeLV）為反轉錄病毒，可導致免疫抑制、貧血、淋巴瘤和其他腫瘤。是貓最重要的致死性傳染病之一。",
    "synonyms": ["FeLV感染", "貓白血病"],
    "epidemiology": {
      "species": "貓",
      "age": "幼貓最易感（<4月齡），隨年齡增長抵抗力增強",
      "sex": "公貓感染風險較高（戶外打鬥）",
      "riskFactors": ["戶外接觸其他貓", "多貓環境", "幼齡", "與感染貓密切接觸（互舔、共用食碗）"]
    },
    "clinicalPresentation": {
      "history": ["慢性反覆感染", "消瘦", "食慾下降", "慢性口腔炎", "反覆發燒"],
      "physicalExam": ["蒼白黏膜（貧血）", "淋巴結腫大", "脾腫大", "口腔炎/齒齦炎", "腫瘤腫塊", "黃疸", "體況差"]
    },
    "pathophysiology": "FeLV經口鼻感染，在口咽淋巴組織複製，經血行擴散至骨髓。可整合入宿主基因組。感染結局包括：進行性感染（持續病毒血症）、退行性感染（潛伏）、短暫性感染（清除）或不完全感染。進行性感染導致免疫抑制、骨髓異常、腫瘤形成。",
    "diagnosis": {
      "overview": "SNAP檢測為初步篩查，需確認試驗和結果解讀。",
      "differentials": ["FIV感染", "其他免疫抑制原因", "原發性淋巴瘤", "原發性貧血"],
      "initialDB": ["SNAP ELISA快速檢測（p27抗原）", "全血球計數", "血液抹片", "血清生化"],
      "advanced": ["IFA確認試驗（骨髓感染確認）", "PCR（偵測前病毒DNA）", "骨髓抽吸（貧血或血球異常時）", "分期檢查（X光、超音波）"]
    },
    "treatment": {
      "overview": "無特效抗病毒治療。以支持療法、管理併發症和維持生活品質為主。",
      "acute": ["治療繼發感染（積極抗生素）", "輸血（嚴重貧血）", "支持療法"],
      "chronic": ["室內隔離飼養", "定期健康檢查（每6個月）", "及時治療繼發感染", "淋巴瘤化療", "干擾素輔助（效果有限）", "營養支持"]
    },
    "prognosis": "進行性感染（持續抗原陽性）中位存活約2.5-3年。約70%在3年內死於相關疾病。退行性感染可長期存活。FeLV相關淋巴瘤對化療有一定反應但預後較FeLV陰性差。",
    "pearls": ["初次SNAP陽性應在30天後重新檢測確認", "IFA陽性代表骨髓感染，較難逆轉", "疫苗可有效預防但無法治療已感染貓", "FeLV陽性貓應隔離飼養以保護其他貓"],
    "monitoring": ["每6個月全血球計數和生化", "FeLV抗原追蹤", "體重和臨床症狀", "腫塊發展"],
    "reference": "Hartmann K. J Feline Med Surg 2012; Levy JK et al. J Vet Intern Med 2008"
  },
  "feline-immunodeficiency-virus": {
    "zh": "貓免疫缺陷病毒感染",
    "en": "Feline Immunodeficiency Virus Infection",
    "definition": "由貓免疫缺陷病毒（慢病毒屬反轉錄病毒）引起的慢性免疫抑制疾病，與人類HIV相似但不傳染人。",
    "synonyms": ["FIV感染", "貓愛滋"],
    "epidemiology": {
      "species": "貓",
      "age": "中年成年貓最常診斷（因潛伏期長）",
      "sex": "公貓顯著多於母貓（3:1，因打鬥傳播）",
      "riskFactors": ["未絕育公貓", "戶外活動", "打鬥行為", "多貓環境"]
    },
    "clinicalPresentation": {
      "history": ["慢性口腔炎", "反覆上呼吸道感染", "慢性腹瀉", "消瘦", "打鬥傷口史"],
      "physicalExam": ["慢性齒齦口腔炎", "淋巴結腫大", "體況差", "慢性鼻炎", "皮膚感染", "神經症狀（晚期）"]
    },
    "pathophysiology": "FIV主要經咬傷傳播。感染CD4+ T淋巴細胞並逐漸耗竭。分為急性期（短暫病毒血症、淋巴結腫大）、無症狀攜帶期（可長達數年）和終末期（AIDS-like，嚴重免疫抑制）。CD4/CD8比值倒轉是特徵。",
    "diagnosis": {
      "overview": "SNAP抗體檢測為初步篩查。母源抗體可造成幼貓假陽性。",
      "differentials": ["FeLV感染", "其他免疫抑制原因", "慢性口腔炎其他原因", "淋巴瘤"],
      "initialDB": ["SNAP ELISA抗體快速檢測", "全血球計數（淋巴球減少）", "血清生化"],
      "advanced": ["Western Blot確認", "PCR（前病毒DNA）", "CD4/CD8比值", "病毒載量"]
    },
    "treatment": {
      "overview": "無特效抗病毒治療。重點為管理併發症、預防繼發感染和維持生活品質。",
      "acute": ["積極治療繼發感染", "口腔炎治療（全口拔牙常有效）", "支持療法"],
      "chronic": ["室內飼養（保護自身和其他貓）", "定期健康檢查", "及時治療感染", "營養支持", "口腔疾病管理", "避免免疫抑制藥物"]
    },
    "prognosis": "無症狀攜帶期可長達數年甚至終身。許多FIV陽性貓可維持良好生活品質多年。一旦進入終末期免疫抑制，預後較差。中位存活自診斷起約5年。",
    "pearls": ["FIV陽性貓不等於立即安樂死，多數可正常生活多年", "幼貓<6月齡陽性應在6月齡後重新檢測（排除母源抗體）", "口腔炎是FIV最常見的臨床問題", "FIV疫苗會導致抗體檢測陽性，目前已不建議使用"],
    "monitoring": ["每6個月健康檢查", "全血球計數（CD4淋巴球）", "體重", "口腔健康", "繼發感染徵兆"],
    "reference": "Hartmann K. Vet Clin North Am 2012; Levy JK et al. JFMS 2008"
  },
  "canine-distemper": {
    "zh": "犬瘟熱",
    "en": "Canine Distemper",
    "definition": "由犬瘟熱病毒（副黏液病毒科Morbillivirus屬）引起的高度傳染性多系統疾病，影響呼吸、消化、皮膚和中樞神經系統。",
    "synonyms": ["犬瘟", "Canine Distemper Virus Infection", "CDV"],
    "epidemiology": {
      "species": "犬及其他犬科動物",
      "age": "3-6月齡幼犬最易感（母源抗體消退後）",
      "sex": "無性別傾向",
      "riskFactors": ["未接種疫苗或疫苗不完整", "收容所環境", "幼犬", "免疫抑制"]
    },
    "clinicalPresentation": {
      "history": ["發燒（雙峰熱）", "眼鼻分泌物", "咳嗽", "嘔吐腹瀉", "抽搐", "收容所或未疫苗史"],
      "physicalExam": ["黏液膿性眼鼻分泌物", "肺部囉音", "脫水", "鼻鏡和腳墊過度角化（硬墊症）", "肌陣攣（myoclonus）", "癲癇發作", "共濟失調", "視力障礙"]
    },
    "pathophysiology": "經氣溶膠或接觸感染，首先在呼吸道淋巴組織複製，隨後病毒血症擴散至全身淋巴組織、上皮細胞和中樞神經系統。導致淋巴球壞死（免疫抑制）、上皮細胞損傷和脫髓鞘性腦炎。神經症狀可在呼吸/消化症狀後數週出現。",
    "diagnosis": {
      "overview": "結合臨床表現、疫苗史和實驗室檢查。確診需病毒學檢測。",
      "differentials": ["犬傳染性肝炎", "犬小病毒腸炎", "犬傳染性氣管支氣管炎", "弓蟲症", "肉芽腫性腦膜腦炎"],
      "initialDB": ["全血球計數（早期淋巴球減少）", "結膜或鼻腔拭子RT-PCR", "犬瘟熱快速抗原檢測", "胸部X光（間質性肺炎）"],
      "advanced": ["血清學（IgM抗體）", "腦脊液分析和PCR（神經型）", "MRI（腦部病變）", "組織病理（包涵體）"]
    },
    "treatment": {
      "overview": "無特效抗病毒治療。支持療法為主，治療繼發感染並控制神經症狀。",
      "acute": ["靜脈輸液糾正脫水", "廣效抗生素（繼發感染）", "止吐止瀉", "營養支持", "隔離防疫"],
      "chronic": ["抗癲癇藥物（神經症狀）", "物理治療", "肌陣攣可能為永久性", "硬墊症的護理"]
    },
    "prognosis": "死亡率50-90%（視毒株和免疫狀態）。出現神經症狀者預後極差。康復犬可能留有永久性神經後遺症（肌陣攣、癲癇、硬墊症）。存活幼犬可能有牙釉質發育不全。",
    "pearls": ["肌陣攣（rhythmic myoclonus）是犬瘟熱幾乎病理性的特徵", "硬墊症是犬瘟熱的經典但非必要的表現", "疫苗是最有效的預防手段", "老犬腦炎可能是犬瘟熱的晚期表現"],
    "monitoring": ["神經症狀進展", "繼發感染", "營養狀態", "隔離措施", "同居犬疫苗狀態"],
    "reference": "Greene CE. Infectious Diseases of the Dog and Cat, 4th Ed. 2012; Martella V et al. Vet Microbiol 2008"
  },
  "keratoconjunctivitis-sicca": {
    "zh": "乾性角結膜炎",
    "en": "Keratoconjunctivitis Sicca",
    "definition": "淚液水層分泌不足導致的角膜和結膜慢性發炎性疾病。是犬最常見的眼表面疾病之一。",
    "synonyms": ["KCS", "乾眼症", "Dry Eye"],
    "epidemiology": {
      "species": "犬較常見，貓少見",
      "age": "中老年犬，但免疫介導性可在任何年齡發生",
      "sex": "母犬略多",
      "riskFactors": ["品種傾向（西施犬、鬥牛犬、可卡犬、巴哥、約克夏）", "短頭犬種", "Sulfonamide藥物使用", "全身麻醉後暫時性", "甲狀腺低下"]
    },
    "clinicalPresentation": {
      "history": ["慢性眼睛分泌物（黏液膿性）", "反覆結膜炎", "眼睛紅腫", "頻繁眨眼或搔眼"],
      "physicalExam": ["角膜表面無光澤乾燥", "黏液膿性分泌物", "結膜充血", "角膜血管新生", "角膜色素沉著", "角膜潰瘍（繼發）", "角膜混濁"]
    },
    "pathophysiology": "約75%犬KCS為免疫介導性淚腺炎，淚腺腺泡受T淋巴細胞浸潤破壞。其他原因包括藥物毒性（Sulfonamide、Etodolac）、神經源性（顏面神經麻痺）、先天性淚腺發育不全。淚液不足導致角膜上皮乾燥、發炎、感染和進行性纖維化。",
    "diagnosis": {
      "overview": "Schirmer淚液試驗（STT）是診斷金標準。",
      "differentials": ["過敏性結膜炎", "細菌性結膜炎", "角膜潰瘍", "眼瞼內翻"],
      "initialDB": ["Schirmer淚液試驗I（正常犬>15mm/min，<10mm確診KCS）", "螢光素染色（排除角膜潰瘍）", "眼壓測量"],
      "advanced": ["淚膜破裂時間（BUT）", "Bengal Rose染色", "淚腺組織切片（少用）", "甲狀腺功能檢查"]
    },
    "treatment": {
      "overview": "免疫介導性以環孢素或他克莫司（Tacrolimus）為主要治療。需終身用藥。",
      "acute": ["人工淚液頻繁使用", "治療繼發感染（局部抗生素）", "角膜潰瘍處理"],
      "chronic": ["環孢素眼用製劑（Optimmune 0.2%）每日兩次", "Tacrolimus 0.03%眼藥（環孢素無效時）", "人工淚液輔助", "定期清潔眼部分泌物", "手術（腮腺管轉位術，藥物無效時）"]
    },
    "prognosis": "免疫介導性KCS對環孢素或Tacrolimus治療反應良好（約75-85%改善）。需終身治療，停藥會復發。早期治療效果較好，長期角膜損傷可能不可逆。",
    "pearls": ["STT應在任何眼科檢查操作之前進行", "Tacrolimus效力約為環孢素的4倍", "藥物反應通常需2-6週才完全顯現", "Sulfonamide引起的KCS可能為不可逆"],
    "monitoring": ["STT每月追蹤至穩定，後每3-6個月", "角膜健康評估", "藥物依從性", "繼發感染"],
    "reference": "Hartley C. In Practice 2010; Maggs DJ. Slatter's Fundamentals of Veterinary Ophthalmology, 6th Ed. 2018"
  },
  "corneal-ulcer": {
    "zh": "角膜潰瘍",
    "en": "Corneal Ulcer",
    "definition": "角膜上皮及可能深層基質的缺損，常因外傷、感染或角膜營養障礙引起，是小動物眼科最常見的急診之一。",
    "synonyms": ["角膜糜爛", "角膜缺損", "Corneal Erosion", "Ulcerative Keratitis"],
    "epidemiology": {
      "species": "犬貓皆常見",
      "age": "任何年齡",
      "sex": "無性別傾向",
      "riskFactors": ["短頭犬種（眼球突出、瞬目不全）", "KCS（乾眼症）", "外傷", "眼瞼異常（內翻、睫毛異位）", "貓皰疹病毒感染"]
    },
    "clinicalPresentation": {
      "history": ["突然眼睛疼痛", "流淚", "頻繁眨眼或閉眼", "眼睛分泌物", "畏光"],
      "physicalExam": ["螢光素染色陽性（上皮缺損）", "結膜充血", "眼瞼痙攣", "角膜水腫", "前房蓄膿（感染性深層潰瘍）", "角膜融解（melting ulcer：嚴重感染）", "Descemet膜膨出（即將穿孔）"]
    },
    "pathophysiology": "角膜上皮損傷後暴露基質層，基質膠原蛋白易受細菌蛋白酶和內源性MMPs分解。表層潰瘍可在3-7天內上皮化癒合。感染或基質融解時，基質蛋白酶快速降解膠原蛋白導致角膜穿孔風險。犬的自發性慢性角膜上皮缺損（SCCEDs/拳師犬潰瘍）因上皮與基質間附著異常而不癒合。",
    "diagnosis": {
      "overview": "螢光素染色是診斷角膜潰瘍的基本工具。需評估深度和有無感染。",
      "differentials": ["角膜異物", "KCS", "青光眼", "前葡萄膜炎", "角膜基質膿腫"],
      "initialDB": ["螢光素染色", "裂隙燈檢查（深度評估）", "STT（排除KCS）", "眼壓測量（排除青光眼）"],
      "advanced": ["角膜細胞學和培養（感染性潰瘍）", "角膜刮片", "眼部超音波（穿孔疑慮）", "貓：FHV-1 PCR"]
    },
    "treatment": {
      "overview": "依深度分級治療。表層潰瘍局部抗生素即可，深層潰瘍或融解性潰瘍為眼科急診。",
      "acute": ["局部廣效抗生素（每4-6小時）", "局部散瞳止痛劑（Atropine）", "Elizabethan collar防止搔抓", "融解性潰瘍：加用血清eye drops和局部MMP抑制劑", "深層/即將穿孔：結膜瓣手術或角膜移植"],
      "chronic": ["SCCEDs：角膜清創術+格柵角膜切開術", "治療潛在原因（矯正眼瞼異常、KCS治療）", "FHV-1相關：抗病毒眼藥（Famciclovir全身性）"]
    },
    "prognosis": "單純表層潰瘍3-7天癒合，預後極佳。深層潰瘍和融解性潰瘍需積極治療，可能需手術。角膜穿孔為眼科急診。SCCEDs清創後癒合率約80-90%。",
    "pearls": ["絕對禁止在角膜潰瘍使用局部類固醇", "融解性潰瘍（melting ulcer）是急診，角膜可能在24小時內穿孔", "自體血清eye drops含有抗蛋白酶可抑制角膜融解", "持續不癒合的潰瘍應排除異物、睫毛異常和KCS"],
    "monitoring": ["每24-48小時螢光素重新評估（深層潰瘍）", "感染控制", "癒合進度", "併發症（前葡萄膜炎、穿孔）"],
    "reference": "Maggs DJ. Slatter's Fundamentals of Veterinary Ophthalmology, 6th Ed. 2018; Gelatt KN. Vet Ophthalmol 2021"
  },
  "brachycephalic-obstructive-airway-syndrome": {
    "zh": "短頭顱阻塞性呼吸道症候群",
    "en": "Brachycephalic Obstructive Airway Syndrome",
    "definition": "短頭犬種因頭顱結構異常導致上呼吸道多處阻塞的綜合症候群，包括鼻孔狹窄、軟顎過長、喉囊外翻和喉部塌陷。",
    "synonyms": ["BOAS", "短頭症候群", "Brachycephalic Syndrome"],
    "epidemiology": {
      "species": "犬較常見（法鬥、英鬥、巴哥、波士頓梗、北京犬），貓偶見（波斯貓、異短）",
      "age": "先天性，症狀可從幼年出現並隨年齡惡化",
      "sex": "無明顯性別差異",
      "riskFactors": ["短頭犬種", "肥胖（加重症狀）", "高溫高濕環境", "激動或運動"]
    },
    "clinicalPresentation": {
      "history": ["打鼾", "運動不耐", "呼吸困難", "熱天症狀加重", "進食困難或反流", "睡眠呼吸暫停", "暈厥"],
      "physicalExam": ["吸氣性喘鳴音（stertor/stridor）", "鼻孔狹窄", "張口呼吸", "發紺（嚴重時）", "軟顎過長", "過度喘息", "體溫升高"]
    },
    "pathophysiology": "先天性頭顱骨短縮但軟組織未按比例縮減，導致：(1)鼻孔狹窄增加吸氣阻力，(2)軟顎過長阻塞喉頭入口，(3)增加的負壓導致繼發性喉囊外翻和喉部塌陷。長期上呼吸道阻塞導致呼吸道繼發性變化加重（惡性循環）。同時常伴有消化道問題（食道裂孔疝、胃食道反流）。",
    "diagnosis": {
      "overview": "臨床表現和品種即可高度懷疑。確切評估需全身麻醉下喉鏡檢查。",
      "differentials": ["喉麻痺", "氣管塌陷", "喉部腫瘤", "異物"],
      "initialDB": ["臨床評估（呼吸音、鼻孔評估）", "頸胸部X光", "BOAS功能分級"],
      "advanced": ["麻醉下喉鏡和氣管內視鏡", "CT掃描（詳細解剖評估）", "消化道內視鏡（評估併發GI問題）", "睡眠監測"]
    },
    "treatment": {
      "overview": "手術矯正為主要治療。早期手術效果較好，可預防繼發性變化。",
      "acute": ["氧氣補充", "降溫（過熱時）", "鎮靜（減少焦慮和呼吸努力）", "短期類固醇減輕喉部水腫", "嚴重者氣管插管或緊急氣管切開"],
      "chronic": ["鼻孔擴張術（Alar fold resection）", "軟顎切短術（Staphylectomy）", "喉囊切除", "體重管理", "避免過熱和劇烈運動", "抗酸劑（併發GI問題時）"]
    },
    "prognosis": "早期手術矯正預後良好，約90%犬顯著改善。喉部塌陷（Grade III）預後較差。術後需長期體重和環境管理。法鬥和英鬥的手術和麻醉風險較其他品種高。",
    "pearls": ["短頭犬種麻醉和手術風險較高，拔管需特別謹慎", "肥胖管理是非手術最重要的措施", "GI症狀（反流、嘔吐）與BOAS高度相關", "年輕時手術可預防繼發性喉部塌陷"],
    "monitoring": ["術後呼吸評估", "體重管理", "運動耐受度", "GI症狀"],
    "reference": "Meola SD. Vet Clin North Am 2013; Liu NC et al. PLoS ONE 2017"
  },
  "tracheal-collapse": {
    "zh": "氣管塌陷",
    "en": "Tracheal Collapse",
    "definition": "氣管軟骨環退化導致氣管管腔動態性塌陷，引起慢性咳嗽和呼吸困難。主要影響中老年小型犬。",
    "synonyms": ["氣管軟化症", "Tracheomalacia"],
    "epidemiology": {
      "species": "犬（小型犬），貓極罕見",
      "age": "中老年犬（6-7歲以上），但可更早出現",
      "sex": "無明顯性別差異",
      "riskFactors": ["小型犬種（約克夏、博美、吉娃娃、貴賓、馬爾濟斯）", "肥胖", "牽繩拉扯頸部", "呼吸道感染", "二手煙"]
    },
    "clinicalPresentation": {
      "history": ["慢性鵝叫聲咳嗽（goose-honk cough）", "激動或運動後咳嗽加重", "拉牽繩時咳嗽", "進行性呼吸困難", "暈厥"],
      "physicalExam": ["觸壓氣管誘發咳嗽", "吸氣性（頸段塌陷）或呼氣性（胸段塌陷）呼吸困難", "可能併發心臟雜音", "肥胖", "發紺（嚴重發作時）"]
    },
    "pathophysiology": "氣管軟骨環中糖胺聚糖和硫酸軟骨素含量減少，導致軟骨失去結構支撐力。背側氣管膜鬆弛下垂。頸段氣管在吸氣時塌陷（負壓），胸段和主支氣管在呼氣時塌陷（正壓）。咳嗽和發炎進一步加重氣管損傷形成惡性循環。",
    "diagnosis": {
      "overview": "結合臨床症狀、影像學和氣管鏡檢查。動態評估很重要。",
      "differentials": ["慢性支氣管炎", "心臟病（咳嗽）", "BOAS", "喉麻痺", "肺腫瘤"],
      "initialDB": ["頸胸部X光（吸氣和呼氣相）", "觸診氣管", "心臟評估（排除心臟病）"],
      "advanced": ["透視檢查（動態氣管評估，金標準分級）", "氣管支氣管鏡（直視分級和取樣）", "CT掃描", "心臟超音波"]
    },
    "treatment": {
      "overview": "輕中度以內科治療為主。嚴重或內科難治性考慮氣管支架或手術。",
      "acute": ["鎮靜（Butorphanol）", "氧氣補充", "短期類固醇（減輕氣管發炎）", "支氣管擴張劑"],
      "chronic": ["體重管理（極重要）", "止咳藥（Hydrocodone、Butorphanol）", "支氣管擴張劑（Theophylline）", "改用胸背帶取代項圈", "避免刺激物和過熱", "氣管內支架（嚴重病例）", "氣管外環固定術（頸段）"]
    },
    "prognosis": "內科治療多數可控制症狀多年。進行性疾病，可能逐漸惡化。氣管支架可顯著改善嚴重病例但可能有併發症（支架移位、肉芽組織增生）。合併肺高壓或支氣管塌陷者預後較差。",
    "pearls": ["鵝叫聲咳嗽是氣管塌陷的典型特徵", "70%以上的氣管塌陷犬同時有支氣管塌陷", "項圈壓力可加重氣管塌陷，應改用胸背帶", "常與二尖瓣疾病並存，需同時評估心臟"],
    "monitoring": ["咳嗽頻率和嚴重度", "呼吸功能", "體重", "心臟功能", "支架病例需定期追蹤"],
    "reference": "Johnson LR. Vet Clin North Am 2016; Tappin SW. J Small Anim Pract 2016"
  },
  "feline-asthma": {
    "zh": "貓哮喘",
    "en": "Feline Asthma",
    "definition": "貓下呼吸道的慢性嗜酸球性發炎伴隨支氣管高反應性和可逆性氣道阻塞。是貓最常見的下呼吸道疾病。",
    "synonyms": ["貓支氣管哮喘", "貓過敏性支氣管炎", "Feline Allergic Bronchitis"],
    "epidemiology": {
      "species": "貓",
      "age": "2-8歲常見，任何年齡可發生",
      "sex": "無明顯性別傾向，暹羅貓可能較易感",
      "riskFactors": ["室內環境過敏原（塵蟎、貓砂粉塵、香氛）", "二手煙", "暹羅貓", "肥胖"]
    },
    "clinicalPresentation": {
      "history": ["間歇性咳嗽", "呼吸急促", "張口呼吸（急性發作）", "哮喘發作", "運動不耐", "症狀可能為季節性"],
      "physicalExam": ["呼氣性呼吸努力（腹部用力）", "肺部哮鳴音（wheezes）", "延長呼氣相", "急性發作時發紺", "桶狀胸（慢性空氣滯留）"]
    },
    "pathophysiology": "吸入性過敏原引發氣道Th2型免疫反應，嗜酸球浸潤氣道壁，肥大細胞脫顆粒釋放組織胺和白三烯。導致支氣管平滑肌痙攣、黏液過度分泌和氣道壁增厚。慢性病例可發生氣道重塑（平滑肌增生、纖維化）。",
    "diagnosis": {
      "overview": "結合臨床表現、X光和排除其他原因。確診需氣管沖洗細胞學。",
      "differentials": ["心絲蟲相關呼吸道疾病", "肺蟲感染", "肺腫瘤", "胸腔積液", "心臟病"],
      "initialDB": ["胸部X光（支氣管壁增厚、肺過度充氣）", "全血球計數（嗜酸球增多，約20%病例）", "心絲蟲抗體/抗原檢測", "糞便浮游法（排除肺蟲）"],
      "advanced": ["支氣管肺泡灌洗（BAL）細胞學（嗜酸球>17%）", "氣管鏡", "胸部CT", "過敏原檢測"]
    },
    "treatment": {
      "overview": "類固醇抗炎和支氣管擴張劑為治療核心。吸入療法可減少全身性副作用。",
      "acute": ["氧氣補充（氧氣籠）", "注射Terbutaline（支氣管擴張，0.01mg/kg SC/IM）", "短效注射類固醇（Dexamethasone IV）", "最小化壓力和操作"],
      "chronic": ["吸入類固醇（Fluticasone MDI + AeroKat spacer）", "口服Prednisolone（逐漸減至最低有效劑量）", "吸入支氣管擴張劑（Albuterol急救用）", "環境過敏原控制", "無塵貓砂", "減敏治療（已知過敏原時）"]
    },
    "prognosis": "多數貓對治療反應良好，可長期控制。慢性氣道重塑可能導致不可逆性氣道阻塞。急性嚴重發作可能致命。吸入療法是長期管理的最佳選擇。",
    "pearls": ["貓的咳嗽幾乎總是呼吸道疾病（不像犬常為心臟病）", "急性發作時避免過度壓力和操作，貓可能因應激加重呼吸衰竭", "AeroKat spacer讓貓吸入類固醇治療成為可能", "心絲蟲相關呼吸道疾病臨床表現與哮喘幾乎相同"],
    "monitoring": ["呼吸頻率和努力程度", "咳嗽頻率", "X光追蹤", "類固醇副作用（糖尿病風險）"],
    "reference": "Reinero CR. J Feline Med Surg 2011; Trzil JE. Vet Clin North Am 2020"
  },
  "periodontal-disease": {
    "zh": "牙周病",
    "en": "Periodontal Disease",
    "definition": "影響牙齒周圍支持結構（牙齦、牙周韌帶、齒槽骨和牙骨質）的發炎性和破壞性疾病。是犬貓最常見的疾病。",
    "synonyms": ["牙周炎", "齒齦炎", "Periodontitis"],
    "epidemiology": {
      "species": "犬貓皆極常見",
      "age": "隨年齡增加，3歲以上犬貓>80%有某種程度的牙周病",
      "sex": "無性別傾向",
      "riskFactors": ["小型犬種（牙齒擁擠）", "缺乏口腔護理", "乾糧不能有效預防", "免疫抑制", "牙齒排列不正"]
    },
    "clinicalPresentation": {
      "history": ["口臭", "進食困難或偏好軟食", "流涎", "面部腫脹", "鼻分泌物（口鼻瘺管）", "齒齦出血"],
      "physicalExam": ["牙結石堆積", "齒齦紅腫（齒齦炎）", "齒齦退縮", "牙齒鬆動", "牙周囊袋", "口鼻瘺管", "下頷骨骨折（嚴重小型犬）"]
    },
    "pathophysiology": "牙菌斑（細菌生物膜）附著牙齒表面，引發齒齦發炎。未治療時細菌向齦下發展，發炎反應破壞牙周韌帶和齒槽骨。厭氧菌（如Porphyromonas、Fusobacterium）在深層囊袋中增殖。最終牙齒失去支持結構。全身性影響包括菌血症和可能的心臟、腎臟、肝臟損傷。",
    "diagnosis": {
      "overview": "完整評估需全身麻醉下牙科檢查和X光。清醒檢查僅能初步評估。",
      "differentials": ["口腔腫瘤", "貓牙吸收病變（FORL）", "口腔炎", "自體免疫性口腔疾病"],
      "initialDB": ["清醒口腔檢查", "全身麻醉下牙周探針檢查", "牙科X光（齒槽骨流失評估）"],
      "advanced": ["全口牙科X光系列", "細菌培養（難治性病例）", "組織切片（排除腫瘤）"]
    },
    "treatment": {
      "overview": "專業牙科清潔是核心治療。嚴重牙周病的牙齒需拔除。家庭口腔護理是預防復發的關鍵。",
      "acute": ["全身麻醉下專業牙科清潔（洗牙）", "齦下刮治和根面整平", "不可救治牙齒的拔除", "局部和/或全身性抗生素", "止痛"],
      "chronic": ["每日刷牙（最有效的家庭護理）", "牙科專用食糧", "口腔沖洗液", "VOHC認證口腔護理產品", "定期專業牙科檢查和清潔"]
    },
    "prognosis": "齒齦炎（早期）完全可逆。牙周炎造成的骨質流失不可逆但可阻止進展。拔除嚴重病牙後犬貓生活品質顯著改善。預防性護理可大幅延緩疾病進展。",
    "pearls": ["非麻醉洗牙（NAD）無法進行齦下治療，不建議作為牙周治療", "每日刷牙是最有效的牙菌斑控制方法", "小型犬的下頷骨可因嚴重牙周病而病理性骨折", "牙科疾病被認為與心臟、腎臟疾病有關聯"],
    "monitoring": ["口腔檢查頻率依嚴重度", "家庭護理依從性", "全身健康影響"],
    "reference": "Niemiec BA. Vet Clin North Am 2013; Bellows J et al. JAVMA 2019"
  },
  "chocolate-toxicosis": {
    "zh": "巧克力中毒",
    "en": "Chocolate Toxicosis",
    "definition": "犬貓攝入巧克力中的甲基黃嘌呤類物質（可可鹼和咖啡因）導致的中毒，主要影響心血管、中樞神經和泌尿系統。",
    "synonyms": ["可可鹼中毒", "Theobromine Toxicosis"],
    "epidemiology": {
      "species": "犬最常見（不挑食習性），貓偶見",
      "age": "幼犬最常見（好奇亂吃）",
      "sex": "無性別傾向",
      "riskFactors": ["節日期間（巧克力禮盒易取得）", "烘焙巧克力和可可粉毒性最高", "小型犬（每公斤攝入量更大）"]
    },
    "clinicalPresentation": {
      "history": ["攝入巧克力的明確病史", "1-12小時內出現症狀", "嘔吐", "躁動不安", "飲水量增加"],
      "physicalExam": ["嘔吐（可能含巧克力）", "腹瀉", "多尿", "心搏過速", "心律不整", "高度興奮", "肌肉震顫", "癲癇發作（嚴重）", "高體溫"]
    },
    "pathophysiology": "可可鹼和咖啡因為甲基黃嘌呤類，競爭性抑制腺苷受體（CNS興奮）、抑制磷酸二酯酶（增加cAMP，心肌興奮）、增加細胞內鈣離子（平滑肌效應）。犬代謝可可鹼的半衰期約17.5小時，遠長於人類。致死劑量約100-200mg/kg可可鹼。烘焙巧克力含量最高（390-450mg/oz）。",
    "diagnosis": {
      "overview": "主要基於攝入病史和臨床表現。需估算可可鹼攝入量。",
      "differentials": ["咖啡因中毒", "其他興奮劑中毒", "殺蟲劑中毒", "原發性心律不整"],
      "initialDB": ["詳細病史（巧克力種類、量、攝入時間）", "心電圖", "全血球計數和生化"],
      "advanced": ["血清可可鹼和咖啡因濃度", "尿液分析", "持續心電監護"]
    },
    "treatment": {
      "overview": "早期去汙染和支持療法。攝入2小時內催吐最有效。",
      "acute": ["催吐（攝入<2小時，Apomorphine犬/Hydrogen peroxide）", "活性炭吸附（重複給予因腸肝循環）", "靜脈輸液促進排泄", "心律不整治療（Lidocaine）", "抗癲癇（Diazepam）", "導尿管（減少可可鹼膀胱再吸收）"],
      "chronic": ["持續監護至症狀消退", "靜脈輸液", "反覆活性炭（每4-6小時）"]
    },
    "prognosis": "輕中度中毒（<40mg/kg可可鹼）預後良好。早期去汙染顯著改善預後。嚴重心律不整或癲癇者預後較謹慎。死亡率在適當治療下<5%。",
    "pearls": ["烘焙巧克力毒性約為牛奶巧克力的10倍", "白巧克力幾乎不含可可鹼，毒性極低", "可可鹼的腸肝循環使反覆活性炭有效", "導尿管防止膀胱中可可鹼再吸收是獨特的治療考量"],
    "monitoring": ["心電監護（12-24小時）", "神經狀態", "體溫", "尿量"],
    "reference": "Gwaltney-Brant SM. Vet Med 2001; Brutlag A. Vet Clin North Am 2012"
  },
  "anticoagulant-rodenticide-toxicosis": {
    "zh": "抗凝血殺鼠劑中毒",
    "en": "Anticoagulant Rodenticide Toxicosis",
    "definition": "攝入抗凝血殺鼠劑（如Brodifacoum、Bromadiolone等）導致維生素K依賴性凝血因子耗竭，引起致命性出血。",
    "synonyms": ["老鼠藥中毒", "華法林中毒", "Warfarin Toxicosis"],
    "epidemiology": {
      "species": "犬最常見（嗜口性高），貓較少",
      "age": "任何年齡，幼犬較常誤食",
      "sex": "無性別傾向",
      "riskFactors": ["環境中放置老鼠藥", "接觸中毒鼠隻（二次中毒）", "戶外自由活動犬"]
    },
    "clinicalPresentation": {
      "history": ["攝入殺鼠劑的可能病史（常不確定）", "攝入後2-5天出現出血症狀", "虛弱", "呼吸困難", "運動不耐"],
      "physicalExam": ["黏膜蒼白", "瘀斑和瘀點", "鼻出血", "血尿", "血便/黑便", "呼吸困難（胸腔出血或肺出血）", "腹部膨大（腹腔出血）", "關節腫脹（關節內出血）"]
    },
    "pathophysiology": "抗凝血殺鼠劑抑制維生素K環氧化物還原酶（VKORC），阻斷維生素K再生循環。維生素K依賴性凝血因子（II、VII、IX、X）和蛋白C/S無法羧化活化。第二代長效殺鼠劑（Brodifacoum等）半衰期可達數週至數月，需長期維生素K1治療。",
    "diagnosis": {
      "overview": "凝血時間延長結合病史或治療反應確診。出血症狀通常延遲2-5天出現。",
      "differentials": ["DIC", "嚴重肝病", "血友病", "血小板減少症", "其他中毒"],
      "initialDB": ["PT（最敏感，因Factor VII半衰期最短6小時）", "aPTT", "全血球計數（貧血程度）", "血小板計數"],
      "advanced": ["PIVKA試驗", "凝血因子活性", "毒物分析（血液或胃內容物）", "腹部/胸部超音波（出血定位）"]
    },
    "treatment": {
      "overview": "維生素K1是特效解毒劑。嚴重出血需緊急穩定。",
      "acute": ["攝入<2小時：催吐+活性炭", "嚴重出血：新鮮冷凍血漿或全血輸血", "靜脈輸液支持", "維生素K1 SC注射（2.5-5mg/kg，分多點注射）", "勿IV給予維生素K1（過敏反應風險）"],
      "chronic": ["維生素K1口服（2.5-5mg/kg/day，分2次，與脂肪食物同服）", "第二代殺鼠劑需治療4-6週", "第一代（Warfarin）治療1-2週", "停藥48-72小時後複查PT"]
    },
    "prognosis": "早期診斷和正確治療預後極佳。嚴重出血（腦、心包）可能致命。治療期間維生素K1不可中斷。停藥後PT複查確認凝血功能恢復正常。",
    "pearls": ["PT是最早延長的凝血指標（Factor VII半衰期僅6小時）", "維生素K1必須與脂肪食物同服以促進吸收", "停藥後48-72小時必須複查PT確認安全", "維生素K3（Menadione）無效，必須使用K1（Phytonadione）"],
    "monitoring": ["PT（治療前、治療中、停藥後48-72小時）", "PCV/TS", "出血徵兆", "維生素K1依從性"],
    "reference": "Waddell LS et al. JVECC 2013; DeClementi C. Vet Clin North Am 2012"
  },
  "congestive-heart-failure": {
    "zh": "充血性心力衰竭",
    "en": "Congestive Heart Failure",
    "definition": "心臟無法維持足夠的心輸出量以滿足身體代謝需求，導致靜脈壓升高和組織液體滯留。是各種心臟病的終末表現。",
    "synonyms": ["CHF", "心衰竭", "鬱血性心衰竭"],
    "epidemiology": {
      "species": "犬貓皆常見",
      "age": "犬：中老年（二尖瓣疾病）、幼年（先天性）；貓：任何年齡（HCM）",
      "sex": "犬二尖瓣疾病公犬較多，貓HCM公貓較多",
      "riskFactors": ["犬：二尖瓣黏液樣變性（小型犬）、擴張型心肌病（大型犬）", "貓：肥厚型心肌病", "先天性心臟病", "心絲蟲病"]
    },
    "clinicalPresentation": {
      "history": ["運動不耐", "咳嗽（犬左心衰竭）", "呼吸急促/困難", "夜間不安", "食慾下降", "昏厥", "腹部膨大（右心衰竭）"],
      "physicalExam": ["心雜音", "肺部囉音（肺水腫）", "心率加快", "呼吸急促", "腹水（右心衰竭）", "頸靜脈怒張", "黏膜蒼白或發紺", "肝脾腫大", "貓：張口呼吸、呼吸困難"]
    },
    "pathophysiology": "心臟泵血功能不全→心輸出量下降→神經體液代償啟動（RAAS系統、交感神經、ADH）→鈉水滯留、血管收縮→靜脈壓升高→左心衰竭導致肺水腫，右心衰竭導致腹水和體腔積液。代償機制長期反而加速心臟惡化（惡性循環）。",
    "diagnosis": {
      "overview": "結合臨床表現、影像學和生物標記物。需鑑別心因性和非心因性呼吸困難。",
      "differentials": ["原發性呼吸道疾病", "肺炎", "肺腫瘤", "胸腔積液（非心因性）", "貧血"],
      "initialDB": ["胸部X光（心臟大小、肺水腫、胸水）", "心臟超音波（LA/Ao比值、收縮功能）", "心電圖", "NT-proBNP或proBNP"],
      "advanced": ["完整心臟超音波（M-mode、2D、Doppler）", "血壓測量", "全血球計數和生化（腎功能）", "心絲蟲檢測", "Holter監測"]
    },
    "treatment": {
      "overview": "急性穩定以利尿和氧氣為主。慢性管理需多藥物組合治療。",
      "acute": ["Furosemide IV/IM（2-4mg/kg，可每1-2小時重複）", "氧氣補充", "鎮靜（Butorphanol）減輕焦慮", "Pimobendan口服（立即開始）", "嚴重肺水腫：Nitroprusside CRI", "胸腔積液引流（貓）"],
      "chronic": ["Furosemide口服（調至最低有效劑量）", "Pimobendan（犬0.25mg/kg BID）", "ACE抑制劑（Enalapril/Benazepril）", "Spironolactone", "低鈉飲食", "限制劇烈運動", "犬DCM：加用Pimobendan可能延緩病程"]
    },
    "prognosis": "犬二尖瓣疾病CHF中位存活約8-12個月（治療下）。犬DCM中位存活3-6個月。貓HCM/CHF變異大，數月至數年。急性肺水腫死亡率約10-20%。Pimobendan顯著延長犬CHF存活。",
    "pearls": ["犬的咳嗽可能是心臟病但也常是氣管塌陷或支氣管炎", "貓心臟病常無前兆，首發表現可能就是呼吸困難或血栓", "NT-proBNP可幫助區分心因性和呼吸性呼吸困難", "睡眠呼吸頻率（SRR）>30次/分是CHF早期監測指標"],
    "monitoring": ["睡眠呼吸頻率（主人在家監測）", "胸部X光", "心臟超音波（每3-6個月）", "腎功能和電解質", "體重"],
    "reference": "Keene BW et al. ACVIM Consensus Statement. J Vet Intern Med 2019; Luis Fuentes V et al. J Vet Intern Med 2020"
  },
  "pleural-effusion": {
    "zh": "胸腔積液",
    "en": "Pleural Effusion",
    "definition": "胸腔（胸膜腔）內異常液體蓄積，導致肺臟擴張受限和呼吸困難。是臨床重要的急診表現。",
    "synonyms": ["胸水", "胸膜積液", "Hydrothorax"],
    "epidemiology": {
      "species": "犬貓皆常見",
      "age": "任何年齡，視潛在病因而異",
      "sex": "視病因而異",
      "riskFactors": ["心臟病（尤其貓）", "腫瘤", "感染（膿胸）", "乳糜胸", "FIP（貓）", "低白蛋白血症"]
    },
    "clinicalPresentation": {
      "history": ["呼吸困難", "運動不耐", "食慾下降", "咳嗽（犬較常見）", "急性或慢性病程"],
      "physicalExam": ["呼吸急促和努力", "限制性呼吸模式", "腹部呼吸", "腹側肺音減弱", "背側肺音正常（液氣交界）", "心音減弱", "發紺", "貓：張口呼吸"]
    },
    "pathophysiology": "正常胸膜腔僅含少量液體（潤滑用）。胸腔積液因以下機制蓄積：靜脈壓升高（心衰竭→漏出液）、血管通透性增加（感染/腫瘤→滲出液）、淋巴管阻塞（腫瘤→乳糜液）、低膠體滲透壓（低白蛋白→漏出液）、隔膜破裂（尿液、膽汁）。積液壓迫肺臟導致通氣不足和呼吸窘迫。",
    "diagnosis": {
      "overview": "確認積液存在、分類液體性質和尋找潛在病因。胸腔穿刺既是診斷也是治療。",
      "differentials": ["心臟病", "腫瘤（淋巴瘤、胸腺瘤）", "膿胸", "FIP", "乳糜胸", "肺葉扭轉", "橫膈疝", "低白蛋白血症"],
      "initialDB": ["胸部X光（排液前後）", "胸腔穿刺和液體分析（比重、蛋白質、有核細胞計數、細胞學）", "全血球計數和生化"],
      "advanced": ["液體培養（疑似膿胸）", "液體三酸甘油酯和膽固醇（乳糜液鑑別）", "心臟超音波", "胸部超音波引導穿刺", "CT掃描", "FIP相關檢查（貓）"]
    },
    "treatment": {
      "overview": "緊急胸腔穿刺引流緩解呼吸窘迫，同時治療潛在病因。",
      "acute": ["治療性胸腔穿刺（緊急緩解呼吸）", "氧氣補充", "穩定循環（輸液、需要時謹慎以免加重）"],
      "chronic": ["針對潛在病因治療", "心臟病：利尿劑和心臟藥物", "膿胸：胸管引流+長期抗生素", "腫瘤：化療或手術", "乳糜胸：低脂飲食、Rutin、胸管結紮手術", "FIP：GS-441524抗病毒治療", "反覆積液：胸管或胸膜固定術"]
    },
    "prognosis": "取決於潛在病因。感染性（膿胸）積極治療預後良好。腫瘤相關預後較差。心因性胸水可通過心臟病治療控制。FIP過去預後極差但現有抗病毒治療大幅改善。乳糜胸手術治療成功率約50-80%。",
    "pearls": ["貓的胸腔積液最常見原因是心臟病和腫瘤", "呼吸窘迫的貓應先穩定再進行X光檢查", "乳糜液三酸甘油酯>100mg/dL且高於血清值", "膿胸需早期積極引流，單靠抗生素效果不佳"],
    "monitoring": ["呼吸頻率和努力", "X光追蹤液體量", "潛在病因治療反應", "反覆穿刺需求"],
    "reference": "Beatty J et al. J Feline Med Surg 2010; Fossum TW. Small Animal Surgery, 5th Ed. 2019"
  },
  "anaphylaxis": {
    "zh": "過敏性休克",
    "en": "Anaphylaxis",
    "definition": "急性嚴重的全身性第I型過敏反應，可導致心血管塌陷、呼吸衰竭和死亡。犬的休克器官為肝臟和腸道，貓為肺臟。",
    "synonyms": ["全身性過敏反應", "過敏性反應", "Anaphylactic Shock"],
    "epidemiology": {
      "species": "犬貓皆可發生",
      "age": "任何年齡",
      "sex": "無性別傾向",
      "riskFactors": ["先前致敏暴露", "疫苗接種", "蜂螫蟲咬", "藥物過敏（抗生素、NSAIDs）", "血液製品輸注", "食物過敏原"]
    },
    "clinicalPresentation": {
      "history": ["暴露過敏原後數分鐘至數小時發生", "急性虛脫", "嘔吐腹瀉（犬）", "呼吸困難（貓）"],
      "physicalExam": ["犬：急性嘔吐、血便、低血壓、休克", "貓：急性呼吸窘迫、支氣管痙攣、喉頭水腫", "面部/眼瞼水腫（血管性水腫）", "蕁麻疹", "心搏過速", "黏膜蒼白或發紺", "體溫下降"]
    },
    "pathophysiology": "先前致敏後產生的IgE結合肥大細胞和嗜鹼球表面。再次暴露同一過敏原時，IgE交聯引發大規模脫顆粒，釋放組織胺、白三烯、前列腺素等。犬的休克器官為肝靜脈和腸道（肝靜脈充血、腸道出血性壞死）。貓為肺臟（支氣管痙攣、肺水腫）。全身性血管擴張和通透性增加導致循環衰竭。",
    "diagnosis": {
      "overview": "主要為臨床診斷，基於過敏原暴露史和急性全身性反應。",
      "differentials": ["其他原因的休克（敗血性、低容積性、心因性）", "急性胃腸道疾病", "急性呼吸衰竭", "中毒"],
      "initialDB": ["臨床表現和暴露史", "血壓測量", "全血球計數（嗜酸球減少）", "血液氣體分析"],
      "advanced": ["血清tryptase濃度（升高支持診斷）", "過敏原特異性IgE（事後確認）"]
    },
    "treatment": {
      "overview": "Epinephrine是首選急救藥物。同時進行積極的支持療法。",
      "acute": ["Epinephrine IM（0.01-0.02mg/kg，1:1000）- 首選且最重要", "靜脈輸液快速擴容（Shock dose crystalloids）", "氧氣補充", "Diphenhydramine（H1阻斷劑）", "Ranitidine/Famotidine（H2阻斷劑）", "Dexamethasone IV（預防二相反應）", "支氣管擴張劑（支氣管痙攣時）", "必要時氣管插管"],
      "chronic": ["觀察4-24小時（二相反應風險）", "口服抗組織胺2-3天", "短期類固醇", "避免再次暴露已知過敏原", "高風險動物備用Epinephrine"]
    },
    "prognosis": "及時給予Epinephrine和支持療法，多數病例可完全恢復。延遲治療可能致命。約20%可能出現二相反應（4-8小時後再發）。",
    "pearls": ["Epinephrine是唯一的第一線急救藥物，不要延遲給予", "犬的過敏性休克主要表現為嘔吐/腹瀉/肝充血而非支氣管痙攣", "貓的過敏性休克以呼吸道症狀為主", "疫苗後建議觀察15-30分鐘"],
    "monitoring": ["持續心電監護", "血壓", "呼吸功能", "4-24小時觀察二相反應", "過敏原記錄"],
    "reference": "Shmuel DL et al. JVECC 2013; Dowling PM. Can Vet J 2011"
  },
  "food-allergy": {
    "zh": "食物過敏",
    "en": "Food Allergy",
    "definition": "對食物中特定蛋白質成分產生的免疫介導性不良反應，導致皮膚和/或消化道症狀。是犬貓第三常見的過敏性皮膚病。",
    "synonyms": ["食物不良反應", "Adverse Food Reaction", "Cutaneous Adverse Food Reaction", "CAFR"],
    "epidemiology": {
      "species": "犬貓皆常見",
      "age": "任何年齡（<1歲或>6歲發病應高度懷疑）",
      "sex": "無明顯性別傾向",
      "riskFactors": ["品種傾向（拉布拉多、德國牧羊犬、西高地白梗、暹羅貓）", "異位性體質", "慢性腸道發炎"]
    },
    "clinicalPresentation": {
      "history": ["全年性（非季節性）搔癢", "慢性嘔吐/腹瀉", "搔癢對類固醇反應不完全", "可能有耳道感染", "排便頻率增加"],
      "physicalExam": ["犬：面部、耳朵、足部、腋下、腹股溝搔癢（與異位性皮膚炎相似）", "貓：頭頸部搔癢、粟粒性皮膚炎、嗜酸球性肉芽腫", "慢性耳道炎", "肛周搔癢", "繼發性感染"]
    },
    "pathophysiology": "食物蛋白質穿過腸道黏膜屏障後被免疫系統識別為外來抗原，引發IgE介導和/或T細胞介導的免疫反應。最常見的過敏原蛋白質為牛肉、乳製品、雞肉、小麥、大豆（犬）和牛肉、魚、雞肉、乳製品（貓）。過敏原通常為分子量>10kDa的糖蛋白。",
    "diagnosis": {
      "overview": "食物排除試驗是唯一可靠的診斷方法。血清食物過敏原IgE檢測不可靠。",
      "differentials": ["異位性皮膚炎", "跳蚤過敏性皮膚炎", "疥癬", "接觸性皮膚炎", "炎症性腸病"],
      "initialDB": ["排除跳蚤過敏（嚴格跳蚤預防）", "排除外寄生蟲（皮膚刮片）", "食物排除試驗（8-12週）"],
      "advanced": ["新型蛋白質飲食試驗（兔、鹿、袋鼠等動物未曾接觸的蛋白）", "水解蛋白飲食試驗", "食物激發試驗（確認診斷）", "皮膚切片（排除其他疾病）"]
    },
    "treatment": {
      "overview": "確認過敏食物後終身避免。食物排除試驗本身即為治療性診斷。",
      "acute": ["開始食物排除試驗", "治療繼發性感染", "短期止癢（Oclacitinib或短期類固醇）"],
      "chronic": ["長期避免已確認的過敏食物", "選用適當的商業限定成分飲食", "水解蛋白飲食作為替代", "逐步食物激發試驗確認具體過敏原", "治療併發的異位性皮膚炎"]
    },
    "prognosis": "一旦確認過敏食物並嚴格避免，預後極佳。多數犬貓在食物排除後2-6週皮膚症狀改善，消化道症狀可能更早改善。約30%的食物過敏動物同時有環境過敏（異位性皮膚炎）。",
    "pearls": ["食物排除試驗必須嚴格（無零食、調味劑、咬膠），8-12週才有結論", "血清食物過敏原IgE檢測假陽性率高，不建議作為診斷依據", "約30%的食物過敏犬同時有異位性皮膚炎", "食物過敏可在任何年齡首次出現，即使長期食用同一食物"],
    "monitoring": ["排除試驗期間症狀變化", "食物激發反應", "繼發感染控制", "營養均衡評估"],
    "reference": "Mueller RS et al. BMC Vet Res 2016; Olivry T et al. Vet Dermatol 2015"
  }
}
